Vanda Pharmaceuticals Conference Call Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovation to enhance people's happiness. The company has five approved products in the U.S. including: - **Fanapt**: An atypical antipsychotic for bipolar disorder and schizophrenia - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome - **Ponvory**: Approved for multiple sclerosis - **NEREUS**: Recently approved for motion sickness - **Bysanti**: Approved for bipolar disorder and schizophrenia [2][3] Financial Position - Vanda ended the previous year with over **$260 million** in cash and no debt, indicating a strong financial position [3] - Revenue from Fanapt was **$117 million** in 2025, up from just under **$100 million** in 2024, with forecasts for **$150 million to $170 million** in 2026 [13][14] Product Pipeline and Growth Strategy - Vanda aims to grow and diversify revenue through existing products and new approvals, targeting **six approved products** by the end of the year [4] - Upcoming regulatory catalysts include: - **Imsidolimab**: BLA accepted for review with a PDUFA date of **December 12, 2026** [4] - **Bysanti**: Phase 3 study in major depressive disorder (MDD) with results expected by the end of 2026 [7][9] Bysanti's Market Potential - Bysanti's approval is expected to extend the revenue runway for Vanda's psychiatry portfolio, with potential label expansion for MDD [13][14] - The market size for schizophrenia and bipolar disorder is estimated at **10 million** patients, while MDD is approximately **20 million**, indicating significant growth potential [22] - Bysanti's pricing structure is expected to be more favorable than Fanapt, potentially leading to higher revenue [15][16] Commercialization Strategy - Vanda plans to leverage its existing psychiatry sales force for the launch of Bysanti in Q3 2026 [17][19] - The company anticipates that Bysanti could surpass Fanapt in demand due to its growth trajectory and market potential [20] NEREUS and Motion Sickness Market - NEREUS targets a market of **70 million** people in the U.S. experiencing motion sickness, with over **10 million** seeking treatment [51] - The product is expected to command premium pricing due to its favorable side effect profile compared to existing treatments [52] - Launch is anticipated in **mid-2026** [57] Research and Development Milestones - Vanda is focused on advancing its late-stage pipeline, including: - Phase 3 programs for NEREUS in GLP-1 market and Bysanti in MDD - Phase 3 for Fanapt long-acting injectable in schizophrenia [48] Regulatory Challenges - Vanda faced a Complete Response Letter (CRL) for NEREUS in gastroparesis but is pursuing a hearing with the FDA to present its case [78][80] - The company is optimistic about the potential for a favorable outcome based on recent legal victories [78] Future Outlook - Vanda's revenue guidance for 2026 is set at **$230 million to $260 million**, with specific targets for Fanapt, Ponvory, and Hetlioz [40][41] - The company is in an investment phase, expecting higher cash burn in 2026 due to product launches and pipeline investments [47] Conclusion - Vanda Pharmaceuticals is positioned for growth with a strong product pipeline and strategic focus on expanding its market presence in psychiatry and motion sickness. The company is navigating regulatory challenges while preparing for significant product launches in the near future.

Core Viewpoint - Vanda Pharmaceuticals Inc. (VNDA) shares surged over 40% in after-hours trading following FDA approval of BYSANTI, a new treatment for bipolar I disorder and schizophrenia in adults [1] Group 1: Product Approval and Market Impact - The FDA has approved BYSANTI as a first-line therapy for acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults [1] - BYSANTI is expected to be commercially available in the third quarter of this year [1] - Following the approval, VNDA shares closed at $5.76, down 5.57% during regular trading, but rose to $8.30 in after-hours trading [3] Group 2: Intellectual Property and Future Developments - BYSANTI will be protected by regulatory data exclusivity and U.S. patents, with the last patent expiring in 2044, which supports long-term innovation and patient benefits [2] - This approval marks the second new drug for Vanda in less than two months, following the approval of NEREUS for motion-induced vomiting in December 2025 [3] - A phase 3 trial for BYSANTI as a once-daily adjunctive treatment for major depressive disorder (MDD) is currently underway, with results expected this year [3] Group 3: Stock Performance - VNDA has traded between $3.81 and $9.60 over the past year [3]

Company Overview - Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on innovating to enhance people's happiness [2] - The company employs an innovation-led strategy with a successful track record in developing and commercializing therapies over decades [2] Product Portfolio - Vanda has a robust commercial portfolio anchored by four FDA-approved brands: Fanapt (atypical antipsychotic), HETLIOZ (for two orphan sleep disorders), PONVORY (for multiple sclerosis), and the recently approved NEREUS (for motion-induced vomiting) [3] - The company maintains a strong debt-free balance sheet, providing substantial capital for R&D and commercial activities [3] Pipeline and Growth Potential - Vanda has a late-stage growth pipeline with numerous high-potential programs targeting significant unmet needs in billion-dollar markets [4] - The company is positioned for imminent regulatory catalysts, including the recently approved NEREUS [4]

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks experiencing the largest losses [3]

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks recording the largest losses [3]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 100 points, down 0.28% to 48,229.87, NASDAQ down 0.26% to 23,359.33, and S&P 500 down 0.26% to 6,878.07 [1] - European shares were also lower, with the eurozone's STOXX 600 slipping 0.14%, Spain's IBEX 35 Index down 0.27%, London's FTSE 100 down 0.09%, and France's CAC 40 down 0.23% [6] - Asian markets closed mixed, with Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.09%, and India's BSE Sensex gaining 0.64% [7] Commodities - Oil traded up 0.1% to $58.02, while gold traded down 0.8% at $4,351.00, silver down 7.3% to $72.255, and copper fell 1.9% to $5.6710 [5] Company News - Anghami Inc. shares surged 50% to $3.7306 after reporting a year-over-year increase in H1 results [9] - Vanda Pharmaceuticals Inc. shares rose 32% to $9.28 following FDA approval of NEREUS for motion-induced vomiting prevention [9] - Intelligent Bio Solutions Inc. shares increased 102% to $8.27 after announcing a strategic manufacturing partnership with Syrma Johari MedTech [9] - Corcept Therapeutics Incorporated shares dropped 52% to $34.04 after receiving a Complete Response Letter from the FDA for Relacorilant [9] - FuelCell Energy, Inc. shares fell 10% to $7.18 after filing for an amended common stock offering [9] - SMX (Security Matters) Public Limited Company shares decreased 37% to $32.30 [9] Economic Indicators - U.S. initial jobless claims declined by 16,000 to 199,000, compared to market estimates of 220,000 [10] - U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, dipped by 1.934 million barrels, marking the largest weekly decline since mid-November, against market estimates of a 0.9 million-barrel fall [2][10]

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 100 points, down 0.28% to 48,229.87, NASDAQ slipping 0.26% to 23,359.33, and S&P 500 dropping 0.26% to 6,878.07 [1] - European shares also fell, with the eurozone's STOXX 600 down 0.14%, Spain's IBEX 35 Index down 0.27%, London's FTSE 100 down 0.09%, and France's CAC 40 down 0.23% [6] - Asian markets closed mixed, with Hong Kong's Hang Seng Index down 0.87%, China's Shanghai Composite up 0.09%, and India's BSE Sensex up 0.64% [7] Commodities - In commodity trading, oil increased by 0.1% to $58.02, while gold decreased by 0.8% to $4,351.00. Silver fell 7.3% to $72.255, and copper dropped 1.9% to $5.6710 [5] Company News - Anghami Inc. shares surged 50% to $3.7306 following a year-over-year increase in H1 results [9] - Vanda Pharmaceuticals Inc. saw a 32% increase in shares to $9.28 after receiving FDA approval for NEREUS [9] - Intelligent Bio Solutions Inc. shares rose 102% to $8.27 due to a strategic manufacturing partnership with Syrma Johari MedTech [9] - Corcept Therapeutics Incorporated shares plummeted 52% to $34.04 after receiving a Complete Response Letter from the FDA [9] - FuelCell Energy, Inc. shares fell 10% to $7.18 after filing for an amended common stock offering [9] - SMX Public Limited Company shares dropped 37% to $32.30 [9] Economic Indicators - U.S. initial jobless claims decreased by 16,000 to 199,000, better than market estimates of 220,000 [10] - U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, fell by 1.934 million barrels, marking the largest weekly decline since mid-November, compared to market estimates of a 0.9 million-barrel decrease [10][2]

Summary of Key Points Core Viewpoint - FuelCell Energy, Inc. (NASDAQ:FCEL) experienced a significant decline in share price following the announcement of an amended common stock offering, which allows the company to sell up to $200 million in shares [1]. Company Specifics - FuelCell Energy shares dropped by 8.9%, closing at $7.23 after the announcement of the amended sales agreement [1]. - Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a remarkable increase of 107% in share price, reaching $8.51, due to a strategic manufacturing partnership with Syrma Johari MedTech [4]. - ESH Acquisition Corp. (NASDAQ:ESHA) gained 59% to $22.86, while Northann Corp. (NYSE:NCL) rose by 58.2% to $0.3071 [4]. - Aimei Health Technology Co., Ltd (NASDAQ:AFJK) shares surged by 50.3% to $127.00 [4]. - Anghami Inc. (NASDAQ:ANGH) reported a year-over-year increase in H1 results, leading to a 44.6% rise in share price to $3.6000 [4]. - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares increased by 33.1% to $9.36 after receiving FDA approval for NEREUS [4]. - Datavault AI Inc. (NASDAQ:DVLT) gained 32% to $0.6802, while Oriental Rise Holdings Limited (NASDAQ:ORIS) jumped 31% to $1.6001 following a non-binding letter of intent to acquire Hubei Daguan Tea Industry Group [4]. - Urgent.ly Inc. (NASDAQ:ULY) rose 31% to $3.6000 after adjourning its annual stockholder meeting due to insufficient votes [4]. - Momentus Inc. (NASDAQ:MNTS) gained 26.4% to $6.53, and Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose 16.1% to $172.90 after announcing plans to file a new drug application [4]. Market Movements - Corcept Therapeutics Incorporated (NASDAQ:CORT) saw a significant decline of 50.8% to $34.51 after receiving a Complete Response Letter from the FDA [4]. - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) fell 39.2% to $31.30, while Delixy Holdings Limited (NASDAQ:DLXY) dipped 37.2% to $0.8853 [4]. - MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) declined by 30.7% to $0.2831, and Profusa, Inc. (NASDAQ:PFSA) fell 21.3% to $0.0958 after announcing a new distributor partnership in France [4]. - NIO Inc. (NYSE:NIO) experienced a drop of 9.2% to $4.9950, and Wheels Up Experience Inc. (NYSE:UP) fell 6.3% to $0.5844 [4].

Core Insights - U.S. stocks experienced a decline, with the Dow Jones index dropping over 100 points on Wednesday [1] Group 1: Axsome Therapeutics - Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares surged 16.1% to $172.90 after announcing plans to file a new drug application for AXS-12 in January following FDA feedback [1] - The FDA granted Priority Review to Axsome's AXS-05 for Alzheimer's Agitation [1] Group 2: Other Notable Stock Movements - Aimei Health Technology Co., Ltd (NASDAQ:AFJK) shares increased by 50.3% to $127.00 [3] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) saw a gain of 34.4% to $9.45 after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [3] - Jyong Biotech Ltd. (NASDAQ:MENS) rose 11.8% to $4.7107 [3] - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) increased by 7.5% to $3.5598 [3] - Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (NYSE:EDN) rose 6% to $31.93 [3] - mF International Limited (NASDAQ:MFI) gained 4.8% to $19.46 [3] - Plug Power Inc. (NASDAQ:PLUG) increased by 4.1% to $2.0150, with Clear Street analyst Tim Moore upgrading the stock from Hold to Buy and lowering the price target from $3.5 to $3 [3]